^“The oncogenic ErbB-2/ErbB-3 heterodimer is a surrogate receptor of the epidermal growth factor and betacellulin”. Oncogene16 (10): 1249–58. (1998). doi:10.1038/sj.onc.1201642. PMID9546426.
^“Transformation of NIH 3T3 cells by HER3 or HER4 receptors requires the presence of HER1 or HER2”. J. Biol. Chem.271 (7): 3884–90. (1996). doi:10.1074/jbc.271.7.3884. PMID8632008.
^ ab“Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of Survivin”. Oncogene29 (29): 4225–36. (2010). doi:10.1038/onc.2010.180. PMID20498641.
^“Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells”. Clin. Cancer Res.12 (13): 4103–11. (2006). doi:10.1158/1078-0432.CCR-05-2404. PMID16818711.
“Binding of Neu differentiation factor with the extracellular domain of Her2 and Her3”. J. Biol. Chem.270 (41): 24604–8. (1995). doi:10.1074/jbc.270.41.24604. PMID7592681.
“c-erbB3 gene encodes secreted as well as transmembrane receptor tyrosine kinase”. Biochem. Biophys. Res. Commun.192 (3): 1189–97. (1993). doi:10.1006/bbrc.1993.1542. PMID7685162.
“Characterization of a breast cancer cell differentiation factor that specifically activates the HER4/p180erbB4 receptor”. J. Biol. Chem.268 (25): 18407–10. (1993). doi:10.1016/S0021-9258(17)46636-1. PMID7689552.
“High expression of the EGFR in fibroadenomas compared to breast carcinomas”. Anticancer Res.14 (5A): 1679–88. (1995). PMID7847801.
“Expression of c-erbB family gene products in adenoid cystic carcinoma of salivary glands: an immunohistochemical study”. Anticancer Res.15 (6B): 2623–6. (1996). PMID8669836.
“Analysis of Grb7 recruitment by heregulin-activated erbB receptors reveals a novel target selectivity for erbB3”. J. Biol. Chem.273 (13): 7717–24. (1998). doi:10.1074/jbc.273.13.7717. PMID9516479.
“Binding interaction of the heregulinbeta egf domain with ErbB3 and ErbB4 receptors assessed by alanine scanning mutagenesis”. J. Biol. Chem.273 (19): 11667–74. (1998). doi:10.1074/jbc.273.19.11667. PMID9565587.
“Isolation and characterization of four alternate c-erbB3 transcripts expressed in ovarian carcinoma-derived cell lines and normal human tissues”. Oncogene16 (25): 3243–52. (1998). doi:10.1038/sj.onc.1201866. PMID9681822.
“Mutation of a Shc binding site tyrosine residue in ErbB3/HER3 blocks heregulin-dependent activation of mitogen-activated protein kinase”. J. Biol. Chem.273 (33): 20996–1002. (1998). doi:10.1074/jbc.273.33.20996. PMID9694850.
“The phosphatidylinositol 3'-kinase pathway is a dominant growth factor-activated cell survival pathway in LNCaP human prostate carcinoma cells”. Cancer Res.59 (12): 2891–7. (1999). PMID10383151.